Discontinuation of Postmenopausal Hormone Therapy: Impact on the Cardiovascular System and Quality of Life

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT04050592

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04050592
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Finland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04050592. Randomized; triple masking; primary purpose basic science. Start 2020-02-19 (actual); primary completion 2022-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Discontinuation of Postmenopausal Hormone Therapy: Impact on the Cardiovascular System and Quality of Life
Condition
Menopause
Condition
Atherosclerosis
Condition
Cardiovascular Diseases
Condition
Estrogen Replacement Therapy
Intervention (Drug)
Estradiol
Intervention (Other)
Placebo
Lead sponsor
Hanna Savolainen-Peltonen (class: other)
Collaborator
University of Southern California (class: other)

Record details

Record id
cardio:ct-nct04050592
Content hash
25f19598682caada2d679a8e163f75a80a0da861d9c424b115ebdc58721fbf62